Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR signaling in breast cancer: Bad to the bone

(2010) John Foley et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

(2009) B. Corkery et al.   ANNALS OF ONCOLOGY

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

(2008) Maura N. Dickler et al.   BREAST CANCER RESEARCH AND TREATMENT

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

HER4 Intracellular Domain (4ICD) Activity in the Developing Mammary Gland and Breast Cancer

(2008) Frank E. Jones   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA